Your participation matters, and so does your opinion! 🙋🧏♂️📢 Join our first Science Café: ☕🔴 Leave No One Behind! Fostering Inclusion in Clinical Trials on 18th November at 17:00h in Ateneu Barcelonès We’ll be discussing the importance of #inclusivity in #ClinicalTrials and its impact on public health. What barriers are we facing? How can we continue working toward more inclusive clinical trials? Share your perspective with us! Can’t join in person? Participate online! Register now! 👉https://lnkd.in/dSFqtFUA #RBDCOV #ScienceCafé
RBDCOV_EU
Public Health
RBDCOV aims to test the efficacy, tolerability, and safety of two new clinical trails against COVID-19.
About us
The purpose behind the project is to get a new tool to control de pandemic at short-medium and long term. RBDCOV aims to manufacture and test the first recombinant protein-based vaccine to be authorised in Europe beyond the framework of the project. Project funded by the #HorizonEurope programme. During its two years and a half duration, RBDCOV has to guarantee the success of this challenging project, reaching it specific objectives, that are: performing a Phase I/II clinical study of Wuhan variant vaccine in 72 healthy paediatric individuals recruited in Spanish clinical sites; demonstrating the safety and immunogenicity of the new recombinant RBD protein vaccine against the South African and UK variants of SARS-Cov-2 virus in a phase I/II study; manufacturing and tuning COVID-19 recombinant protein vaccines in GMP conditions; designing a clearly path to authorization and commercialization of the vaccine; and involving the general public, as a community, in the project’s design, execution of Phase I/II.
- Industry
- Public Health
- Company size
- 11-50 employees
- Headquarters
- Bruselas
- Type
- Self-Owned
Locations
-
Primary
Get directions
Bruselas, BE
Employees at RBDCOV_EU
Updates
-
RBDCOV invites you to a Science Café☕👩🔬 🔴Leave No One Behind! Fostering Inclusion in Clinical Trials Join us for an engaging discussion on the importance of inclusivity in clinical trials, focusing on key groups: immunocompromised individuals and pediatric populations. We’ll explore the challenges and barriers to inclusivity and its impact on public health and treatment effectiveness. Dr. Beatriz Mothe Pujadas, Dr. Pere Soler-Palacín, and Joan Tallada will share insights from their unique perspectives on this essential topic. This will be an open debate, so you'll have the opportunity to participate! 📍 Where: Sala Segarra - Ateneu Barcelonès (Barcelona) and online 📅 When: Monday, November 18, at 17:00 CET 👥 Who: Open to everyone interested in the topic! 🧏♀️💻 How: It’s free. The event will be in Spanish with English translation. Join us in person or online. Register now and don’t miss out! #RBDCOV #InnovationKillsTheVirus #ScienceCafé
This content isn’t available here
Access this content and more in the LinkedIn app
-
Vaccination remains the most effective way to protect from #COVID19. 🔴That’s why at #RBDCOV, we are committed to developing inclusive and representative clinical trials. Read more in the article below! 🔽🔽 https://lnkd.in/dpbK3XNv
-
Designing clinical trials for children and adolescents requires careful consideration of their unique physiological and developmental needs. Penta Foundation - Child Health Research a key partner, ensures these are prioritised in the #RBDCOV project. 🔴Read our latest specialized article to learn more about this topic: 👉https://lnkd.in/dwfeXv7G #InnovationKillsTheVirus #Inclusive #ClinicalTrials
-
-
#RBDCOV in Figures 🔬 HH-3 Trial: Focused on the safety and immune response of a booster dose in adolescents aged 12 --18. 🔵200+ Participants 🔵Positive Preliminary Results #InnovationKillsTheVirus
-
-
Our latest article is out! 🥽🥼 Discover how Penta Foundation - Child Health Research promotes health equity through inclusive clinical trials, focusing on the importance of including children to achieve widespread immunity. Read the full article here 🔴👉https://lnkd.in/dwfeXv7G #RBDCOV #InnovationKillsTheVirus
-
-
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) is a key partner in the #RBDCOV project, applying their extensive clinical experience to analyse T cell responses using Intracellular Cytokine Assay (ICS) technology. Discover how this technology works in our latest specialised article! 🔴👉 https://lnkd.in/diyXDXZ3 #InnovatioKillsTheVirus
-
-
#RBDCOVTalks is on the air!🔊 Tune in to listen to leading scientists, researchers, medical professionals, and community advocates. Today, Laura Sesma Aguirre 🔴👉https://lnkd.in/djixhdwg, #InnovationKillsTheVirus #RBDCOV
Need a podcast for summer? 🌞🎧 Check out our #RBDCOVTalks episode with Laura Sesma Aguirre, from Zabala Innovation Europe, discussing our #RBDCOV project and why teamwork and data sharing are central in health research. 🎙️ https://lnkd.in/dvdPNKiM #InnovationKillsTheVirus #COVID19 #COVIDVaccine #BIMERVAX
-
-
To test how well the #BIMERVAX vaccine works, our partner research laboratories at Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) and IrsiCaixa have been assessing both the antibody and immune cell responses during the #RBDCOV trials. Have a look at our latest specialised article to learn all about it! 🔴👉https://lnkd.in/diyXDXZ3 #RBDCOV #InnovationKillsTheVirus #immunogenicity
-
-
Need a podcast for summer? 🌞🎧 Check out our #RBDCOVTalks episode with Laura Sesma Aguirre, from Zabala Innovation Europe, discussing our #RBDCOV project and why teamwork and data sharing are central in health research. 🎙️ https://lnkd.in/dvdPNKiM #InnovationKillsTheVirus #COVID19 #COVIDVaccine #BIMERVAX
-